ClinicalTrials.gg
CompletedNCT07588906Updated May 15, 2026

To Compare the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability Between SHR-3167 Injection and Glargine Insulin in Healthy Subjects

A Phase 1 interventional study of SHR-3167 injection;glargine insulin in Healthy Subjects, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 2 months after the study started (first participant enrolled Feb 2024, registered May 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this study is to compare the pharmacodynamic profile of a single subcutaneous dose of SHR-3167 injection versus insulin glargine U100 in healthy subjects.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in the trial and sign the form; as judged by the researcher, the subjects are willing and able to adhere to all trial requirements and restrictions.
  2. Healthy males, aged 18-55 years (inclusive).
  3. (BMI) within the range of 19.0-24.0 kg/m2 (inclusive); weight ≥50 kg.
  4. Venous fasting blood glucose, oral glucose tolerance test (OGTT) 0 h venous glucose \<6.1 mmol/L and >3.9 mmol/L; OGTT 2 h blood glucose \<7.8 mmol/L; insulin release test (IRT) results are normal, or abnormal but judged by the researcher to have no clinical significance; ≤6.0%.
  5. No history of past and/or present abnormalities in the heart, liver, kidneys, digestive system, nervous system, respiratory system, mental health, and metabolic conditions, as judged by the researcher; vital signs, physical examination, , laboratory tests, and chest X-rays show no abnormalities or abnormalities deemed clinically insignificant (as determined by a clinical physician).
  6. Agree to use effective from the time of signing the informed consent form until 6 months after the last dose of the drug, and to refrain from donating sperm during this period.
  7. The researcher judges that the skin at the intended injection site of the investigational drug on the abdominal wall is normal, without fat hypertrophy, skin depressions, skin indurations, scars, inflammation, edema, ulcers, infections, bleeding, or any other condition that may affect the administration of the investigational drug to the subjects.
  8. Capable of good communication with the researcher and able to comply with the trial requirements to complete the study

Exclusion criteria

Exclusion Criteria:

  1. History of diabetes or a first-degree relative with a history of diabetes.
  2. History of hypokalemia, orthostatic hypotension, syncope, blackout, or severe hypoglycemic episodes.
  3. Conditions judged by the investigator to potentially affect drug absorption, distribution, metabolism, excretion, safety assessment, or compliance, or if the investigator believes that participation in the trial poses a safety risk to the subject.
  4. History of poorly controlled acute or chronic respiratory diseases in the 6 months prior to screening, including but not limited to (COPD), severe asthma, severe pneumonia, severe or critical COVID-19, active pulmonary tuberculosis.
  5. Underwent any major surgery in the 6 months prior to screening or planned elective surgery during or within 1 month after dosing. Major surgery is defined as surgery that results in significant tissue trauma to organs within the skull, chest, abdomen, pelvis, or limbs and requires long-term recovery (e.g., organ transplantation, cardiac surgery, or joint replacement).
  6. Donated blood (including blood components) or experienced blood loss exceeding 400mL in the 3 months prior to screening, or received a blood transfusion or blood products.
  7. History of severe reactions or known allergy to the drug, its , insulin, or insulin analogs.
  8. History of drug abuse in the 12 months prior to screening or a positive result on a prohibited substance urine test.
  9. Participated in any approved or unapproved clinical trial of investigational drugs/devices in the 90 days prior to screening, or planned to participate in another clinical trial during or within 1 month after the trial period.
  10. Positive test results for antigen/antibody (HIV), virus surface antigen (HBsAg), virus antibody (anti-HCV), or Treponema pallidum antibody (TP).
  11. Persons who have had an acute illness during the screening period.
  12. Persons who have regularly consumed alcohol in the six months prior to screening (consuming more than 14 units of alcohol per week, with 1 unit approximately equal to 360mL of beer, 45mL of 40% alcohol spirit, or 150mL of wine); or those who have had a positive alcohol breath test at baseline or are unwilling to abstain from alcohol during the trial.
  13. Persons who have smoked an average of more than 5 cigarettes per day in the three months prior to screening, or are unwilling to quit smoking before the completion of all glucose clamp tests.
  14. Persons who have used any prescription drugs, traditional Chinese medicine, herbal medicine, or over-the-counter drugs, supplements, or have received any vaccinations in the four weeks prior to dosing.
  15. Persons who have taken any medications affecting insulin lowering in the 28 days prior to screening (e.g., , diuretics, adrenaline, salbutamol, glucagon, growth hormone, thyroxine, etc.).
  16. Persons who have consumed excessive tea, coffee, or caffeine-containing beverages (≥8 cups, with 1 cup = 250mL) daily in the two weeks prior to dosing, or do not agree to abstain from consuming grapefruit juice or any foods and beverages containing alcohol and xanthine (including chocolate, tea, coffee, cola, etc.) for 48 hours before dosing and until the completion of all glucose clamp tests.
  17. Persons who have made significant changes in diet or exercise habits in the three months prior to screening, such as weight loss or intense exercise.
  18. Persons who are unwilling or unable to follow the lifestyle guidance described in the trial protocol, have special dietary requirements, or cannot adhere to a standardized diet.
  19. Persons who cannot tolerate venipuncture, have difficulty with blood sampling, have a history of fainting or fainting at the sight of needles, or cannot establish a venous route in both upper limbs.
  20. Persons who are directly involved in this trial as staff of the research center or sponsor, or their immediate relatives (spouse, parents/legal guardians, siblings, or children).
  21. Other conditions that the researcher deems unsuitable for the participant to take part in this trial.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    insulin glargine followed by SHR-3167 injection

    Participants will receive a single injection of glargine in the Glargine period and then washout. After that, participants will receive a single injection of SHR-3167 in the SHR-3167 period.

    Drug: SHR-3167 injection;glargine insulin

Interventions

  • Drug: SHR-3167 injection Participants will receive a single subcutaneous (s.c.) injections of SHR-3167 injection Drug: glargine insulin Participants will receive a single subcutaneous (s.c.) injections of glargine insulin

06

What researchers measure

Primary outcomes

  1. Glucose infusion rate (GIR) - area under the curve (AUC)

    Time frame: Glargine period: 0-24hour ; SHR-3167 period: 0-226hour

Secondary outcomes

  1. area under the curve (AUC0-t, AUC0-∞)

    Time frame: 0-1680 hour

  2. maximum concentration (Cmax)

    Time frame: 0-1680 hour

  3. time to reach maximum concentration (Tmax)

    Time frame: 0-1680 hour

  4. half-life (t1/2)

    Time frame: 0-1680 hour

  5. apparent clearance (CL/F)

    Time frame: 0-1680 hour

  6. apparent volume of distribution (Vz/F).

    Time frame: 0-1680 hour

  7. Change in fasting blood glucose from baseline.

    Time frame: 0-1680 hour

  8. Hypoglycemic events

    Time frame: 0-1680 hour

  9. adverse events (AE)

    Time frame: 0-1680 hour

  10. Change in fasting C-peptide from baseline

    Time frame: 0-1680 hour

07

Study locations

1 site
  • Bishan Hospital of Chongqing
    Chongqing, Chongqing Municipality 400000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Jul 2024, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2026
First posted
May 15, 2026
StartActual
Feb 26, 2024
Primary completionActual
Jul 12, 2024
CompletionActual
Jul 23, 2024
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07588906
Responsible party
Sponsor
First posted
May 15, 2026
Start date
Feb 26, 2024
Primary completion
Jul 12, 2024
Completion
Jul 23, 2024
Last update
May 15, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-3167

Start the discussion